Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Income from Continuing Operations (2016 - 2025)

Editas Medicine (EDIT) has disclosed Income from Continuing Operations for 11 consecutive years, with 25116000.0 as the latest value for Q3 2025.

  • Quarterly Income from Continuing Operations rose 59.58% to 25116000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 197649000.0 through Sep 2025, up 6.13% year-over-year, with the annual reading at 237090000.0 for FY2024, 56.38% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 25116000.0 at Editas Medicine, up from 51477000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 18860000.0 in Q4 2023, with the low at 75663000.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 51376235.29, with a median of 53688000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations soared 68.95% in 2023, then plummeted 140.68% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 55255000.0 in 2021, then decreased by 9.92% to 60736000.0 in 2022, then skyrocketed by 68.95% to 18860000.0 in 2023, then tumbled by 140.68% to 45393000.0 in 2024, then soared by 44.67% to 25116000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 25116000.0, 51477000.0, and 75663000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.